Xiaojuan Mi

Silk-Derived Antibacterial Hydrogels: Material Identity, Mechanistic Evidence, and Translation

Hongmei Wang, Bingbing Xia, Yanlin Zhang, Xiaojuan Mi

Silk fibroin (SF)- and silk sericin (SS)-based antibacterial hydrogels are increasingly engineered as local antimicrobial platforms, yet cross-study interpretation is limited by inconsistent material reporting and by conflation of bacterial inhibition with tissue repair. We performed a structured evidence-mapping and critical synthesis …

cn (code pays fourni par la source)

1716-P: Menopausal Stage and Weight Outcomes with Orforglipron vs. Placebo: Post Hoc Subgroup Analysis from ATTAIN-1 and ATTAIN-2

ANDREEA CIUDIN, Beverly Tchang, AMELIA J. BALMAIN, SUZANNE KLISE et autres

Introduction and Objective: Obesity, a chronic progressive disease, is exacerbated by estrogen deficiency during menopause. Orforglipron (OFG), an oral small-molecule, non-peptide GLP-1 receptor agonist, has demonstrated significant body weight (BW) reductions in ATTAIN-1 and -2. This post-hoc analysis evaluates OFG’s effect on …

Nr4a1 regulates microglia overactivation-mediated neuroinflammation to ameliorate cognitive impairment in trigeminal neuralgia rats

Junjie Li, Zhilun Yang, Xiaojuan Mi, Qiang Wang et autres

BACKGROUND: Cognitive impairment affects prognosis and quality of life in patients with trigeminal neuralgia (TN). Modulating hippocampal microglial activation is a promising approach for addressing TN-related cognitive deficits. Nuclear receptor subfamily 4 group A member 1 (Nr4a1) is involved in hippocampal-dependent cognition …

cn (code pays fourni par la source)

The Alzheimer’s Disease Cooperative Study – Activities of Daily Living dependence score: revision and validation of an algorithm evaluating patient dependence across the spectrum of AD severity

Claire J. Lansdall, Wenyu Ye, Fiona McDougall, Mark A. Belger et autres

BACKGROUND: Increasing dependence on informal and formal caregivers in Alzheimer's disease (AD) contributes to high societal cost. Treatments that delay time to increased dependence/care needs would be clinically meaningful, but these outcomes are rarely collected in early AD clinical trials. The 2015 …

us, ch (code pays fourni par la source)

Minocycline ameliorates cognitive impairment in rats with trigeminal neuralgia by regulating microglial polarization

Junjie Li, Xiaojuan Mi, Zi-qi Feng, Yong Min Han et autres

• Cognitive impairment occurs in rats with trigeminal neuralgia. • Minocycline alleviates cognitive impairment in trigeminal neuralgia rats by improving synaptic plasticity. • Minocycline hippocampal neuroinflammation in trigeminal neuralgia rats by modulating the polarization of microglia. • The TLR4/MyD88/NF-κB pathway is involved …

cn (code pays fourni par la source)

Potential Impact of Slowing Disease Progression in Early Symptomatic Alzheimer’s Disease on Patient Quality of Life, Caregiver Time, and Total Societal Costs: Estimates Based on Findings from GERAS-US Study

Julie Chandler, Wenyu Ye, Xiaojuan Mi, Erin Gautier Doty et autres

Background: Impact of Alzheimer's disease (AD) progression on patient health-related quality of life (HRQoL), caregiver time, and societal costs is not well characterized in early AD. Objective: To assess the association of change in cognition with HRQoL, caregiver time, and societal costs …

us (code pays fourni par la source)

Optimization of nitrogen removal and microbial mechanism of a hydrogen-based membrane biofilm reactor

Haixiang Li, Yu Han, Yanhao Zhang, Xiaojuan Mi et autres

The hydrogen-based membrane biofilm reactor (H2-MBfR) is an emerging biological nitrogen removal technology characterized by high efficiency, energy-saving capability, and environmental friendliness. The technology achieves denitrification and denitrogenation of microorganisms by passing hydrogen as an electron donor from inside to outside through …

cn (code pays fourni par la source)

Incremental declines in independence associated with disease progression in early symptomatic Alzheimer’s disease (AD)

Julie Chandler, Wenyu Ye, Xiaojuan Mi, Ellen B. Dennehy et autres

Abstract Background Associations between disease progression (DP) and health outcomes are poorly characterized in mild cognitive impairment (MCI) and mild AD (MILD). To address this, we examined the impact of DP on incremental changes in independent functioning over 18 months; baseline factors …

us (code pays fourni par la source)

Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine

Janet H. Ford, Wenyu Ye, David W. Ayer, Xiaojuan Mi et autres

BACKGROUND: No available studies demonstrate validity and meaningful change thresholds of Work Productivity and Activity Impairment (WPAI) questionnaire in patients with migraine. In this post-hoc analysis, we assessed reliability, validity, responsiveness, and meaningful within-patient change from baseline to Month 3 for Work …

us (code pays fourni par la source)

Annual indirect costs savings in patients with episodic or chronic migraine: a post-hoc analysis of phase 3 galcanezumab clinical trials in the United States

Oralee J. Varnado, Wenyu Ye, Xiaojuan Mi, Russel Thomas Burge et autres

Background Galcanezumab (GMB) improved quality-of-life and reduced disability of patients with episodic (EM) and chronic migraine (CM) in Phase 3 trials.Aim To estimate indirect cost savings associated with GMB treatment in patients with migraine in the United States (US).Methods We analyzed data …

us (code pays fourni par la source)

Potential Savings in Caregiver Time and Societal Costs Associated with Slowing Disease Progression over 36 months in Patients with Early Alzheimer’s Disease: Findings from GERAS‐US

Julie Chandler, Wenyu Ye, Joseph Andrew Johnston, Xiaojuan Mi et autres

Abstract Background Alzheimer’s disease (AD) is associated with significant costs that increase with disease progression. These analyses describe the relationship between cognitive decline and measures of caregiver time and societal costs and estimate the impact of slowing disease progression over 36 months. …

us (code pays fourni par la source)

Annual indirect cost savings in patients with episodic or chronic migraine: post-hoc analyses from multiple galcanezumab clinical trials

Joshua A. Tobin, Janet H. Ford, Antje Tockhorn‐Heidenreich, Russell Nichols et autres

Aim This post-hoc analysis estimated annual indirect cost savings with galcanezumab (GMB) treatment in patients with episodic migraine (EM) or chronic migraine (CM).Methods Data from 4 randomized, Phase 3, double-blind (DB), placebo (PBO)-controlled studies of GMB were analyzed: EVOLVE-1 and EVOLVE-2 (EM, …

us, gb (code pays fourni par la source)